Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects

Abstract

Batifiban, a synthetic cyclic peptide, is a potent platelet glycoprotein GPIIb/IIIa antagonist which may be useful in the treatment and prevention of acute coronary syndromes. The pharmacokinetics and pharmacodymanic (inhibition of platelet aggregation) effects, and tolerability of batifiban were investigated in healthy subjects following single bolus injection with doses of 55, 110, or 220 μg/kg, or multiple doses of an bolus followed intravenous infusion for 24 h (180 μg/kg plus 2.0 μg/min·kg, and 220 μg/kg plus 2.5 μg/min·kg) in this phase I clinical trial. Plasma levels of batifiban and areas under the curve were found to be proportional to doses. Batifiban was rapidly eliminated with a half-life of approximately 2.5 h. Significant differences were noted for plasma levels of batifiban and areas under the curve between males and females. No significant differences in the terminal half-life were found between males and females. Batifiban reversibly inhibited ex vivo platelet aggregation in a dose- and concentration-dependent manner, consistent with its mechanism as a GPIIb/IIIa antagonist. Single and multiple intravenous doses of batifiban were found to be safe and well tolerated in healthy subjects. These results support a bolus injection plus intravenous infusion regimen of batifiban for the treatment and prevention of acute coronary syndromes.

Keywords

Batifiban / GP II b/IIIa integrin receptor / platelet aggregation / pharmacokinetics and pharmacodynamics

References

[1] MadanM., BerkowitzS.D., TchengJ.E.. Glycoprotein IIb/IIIa integrin blockade. Circulation, 1998, 98(23): 2629-2635

[2] KongD.F., CaliffR.M., MillerD.P., et al. . Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation, 1998, 98(25): 2829-2835

[3] SeitzR.J., SieblerM.. Platelet GPIIb/IIa receptor antagonists in human ischemic brain disease. Curr Vasc Pharmacol, 2008, 6(1): 29-36

[4] TricociP., NewbyL.K., KandzariD.E., et al. . Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Rev Cardiovasc Ther, 2007, 5(3): 401-412

[5] GuminaR.J., YangE.H., SandhuG.S., et al. . Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention. Mayo Clin Proc, 2008, 83(9): 995-1001

[6] MandavaP., ThiagarajanP., KentT.A.. Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. Drugs, 2008, 68(8): 1019-1028

[7] DecalfV., SabbahL., LafontA., et al. . GP IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation. Arch Mal Coeur Vaiss, 2007, 100(12): 1006-1012

[8] MoserM., BertramU., PeterK., et al. . Abciximab, eptifibatide, and tirofiban exhibit dose dependent potencies to dissolve platelet aggregates. J Cardiovas Pharmacol, 2003, 41(4): 586-592

[9] HarringtonR.A., KleimanN.S., Kottke-MarchantK., et al. . Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol, 1995, 76(17): 1222-1227

[10] ScarboroughR.M., NaughtonM.A., TengW., et al. . Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem, 1993, 268(2): 1066-1073

[11] JonathanM.G.. Platelet adhesion signaling and the regulation of thrombus formation. J Cell Sci, 2004, 117(pt16): 3415-3425

[12] MousaS.A., BozarthJ.M., ForsytheM.S., et al. . Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet glycoprotein IIb/IIIa receptor antagonist. Circulation, 1994, 89(1): 3-12

[13] LynnS., AnY.C., LiS.. Pharmacokinetic profiles of 2094, an anti-thrombosis agent, in rats, dogs, and cynomolgus monkeys. Asian J Drug Metab Pharmacokinet, 2004, 4(1): 101-112

[14] LiuC.X., WeiG.L., LiQ.S.. Methodology study of validation for bioanalysis in studies on pharmacokinetics and bioavailability. Asian J Drug Metab Pharmacokinet, 2001, 1(4): 279-286

[15] ShahV.P., MidhaK.K., FindlayJ.W., et al. . Bioanalytical method validation—A revisit with a decade of progress. Pharm Res, 2000, 17: 1551-1557

[16] BornG.V., CrossM.J.. The aggregation of blood platelets. J Physiol, 1963, 168: 178-195

[17] AltonK.B., KosoglouT., BakerS., et al. . Disposition of 14C-eptifibatide after intravenous administration to healthy men. Clin Therap, 1998, 20(2): 307-323

[18] GretlerD.D.. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther, 2003, 25(10): 2564-2574

[19] GretlerD.D., GuercioliniR., WilliamsP.J.. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther, 2004, 26(3): 390-398

[20] GilchristI.C., O’sheaJ.C., KosoglouT., et al. . Pharmacodynamics and pharmacokinetics of higher-dose, doublebolus eptifibatide in percutaneous coronary intervention. Circulation, 2001, 104(4): 406-411